Isoprinosine scientific update |
|
 |
|
Int Conf AIDS. 1989 Jun 4-9; 5: 219 (abstract no. Th.B.O.46).
Hidovre
Denmark
Isoprinosine reduced clinical progression in HIV infected patients in a double blind placebo controlled study.
To determine the influence of isoprinosine (Imunovir) on the clinical course of HIV infection. METHODS: A total of 866 HIV infected patients from Sweden and Denmark were randomised and stratified according to CD4-count to receive either isoprinosine 1 g t.i.d. (n=429) or matching placebo (n=437) for 6 months. At baseline the study population consisted of 765 asymptomatic patients and 101 symptomatic patients. Patients with AIDS were not included. RESULTS: Eight hundred and thirty-three patients were eligible for efficacy analysis. There were no significant differences between the two groups with respect to CD4-count or clinical status at baseline. Progression to AIDS according to CDC revised definition: TABULAR DATA, SEE ABSTRACT VOLUME. During treatment no significant differences in CD4-count occurred. No serious side effects were observed. Minor adverse reactions occurred with equal frequencies in both groups. CONCLUSION: Isoprinosine offers a potential treatment modality, particularly in the asymptomatic HIV infected patients. However, the mode of action remains to be clarified.
J Gastrointestin Liver Dis. 2006 Dec;15(4):389-91.
Krastev Z, Antonov K, Jelev DT.
Clinic of Gastroenterology, St.Ivan Rilsky University Hospital, Medical University, Sofia, Bulgaria
The prevention of an expected hepatic flare in HBe negative patients after lamivudine discontinuation.
The treatment with lamivudine leads to drug resistant mutations in 19 to 70% cases after 1- and 5-year therapy, respectively, associated with the risk of
severe rebound of liver disease with alaninaminotransferase flare. In this situation, adefovir should be added, but this drug is not available in every
country. We report three cases where we avoided the expected hepatic flare-ups by using IFN and isoprinosine. Based on this empirical experience, we suggest
that the new drug has to be administered one month before discontinuation of lamivudine. Prospective trials are mandatory.
Acta Derm Venereol. 2006;86(5):422-4.
Georgala S, Katoulis AC, Befon A, Georgala K, Stavropoulos PG.
1st Department of Dermatology and Venereology, "A. Sygros" Hospital, 5, Dragoumi Str.
Inosiplex for Treatment of Alopecia Areata: a Randomized Placebo-controlled Study.
Treatment of alopecia areata remains unsatisfactory. We decided to test if systemic therapy
with inosiplex (Isoprinosine(R)), an immunomodulator could influence the disease. Thirty-two
subjects with recalcitrant alopecia areata, aged 16-48 years (mean 30.3+/-5.1 years), were
randomized into two treatment groups of 16 subjects each. They were assigned to receive either
oral inosiplex (group 1), or placebo (group 2) on a double-blind basis. Inosiplex dosage was
50 mg/kg/day in five divided doses for 12 weeks. Of the 15 evaluable patients in group 1, 5
(33.3%) had full remission, 8 (53.3%) responded partially and 2 (13.3%) did not respond. Of
the 14 evaluable patients in the placebo group, none had full remission, 4 (28.5%) responded
partially and 10 (71.4%) did not respond. The therapeutic difference between patients
receiving active and placebo therapy was statistically significant (?2=7.82, p<0.01). Compared
with placebo, oral inosiplex showed considerable efficacy in alopecia areata with
insignificant side-effects. Larger studies are required, however, before inosiplex may be
recommended as an efficacious and safe alternative systemic form of therapy for recalcitrant
alopecia areata.
Int J Antimicrob Agents. 2000 Apr;14(3):181-91.
Masihi KN.
Robert Koch Institute, Nordufer 20, D-13353, Berlin, Germany.
Immunomodulatory agents for prophylaxis and therapy of infections.
The advent of the antibiotic era ushered in a shift towards non-pathogen-specific therapy of infectious diseases. This led to an overt emphasis on targeting microbial pathogens while strategies directed towards enhancing host immunity were neglected. In an effort to decrease sole reliance on antimicrobials, the time has come for a critical reappraisal of nonantibiotic, albeit immune response-enhancing substances. The diverse array of natural, synthetic, and recombinant immunomodulators discussed in this review succinctly demonstrate the potential of these agents to stimulate host defense mechanisms for prophylaxis and treatment of various microbial infections.
J Helminthol. 2001 Sep;75(3):251-7.
Lawton P, Walchshofer N, Sarciron ME.
Departement de Parasitologie et Mycologie Medicale, Faculte de Pharmacie, Lyon, France.
In vitro effects of isoprinosine and a dipeptide methyl ester on Echinococcus multilocularis protoscoleces.
A protoscoleces/vesicles in vitro maintenance test with assessment of viability by eosin exclusion was used to evaluate the quantitative and qualitative activities of isoprinosine, its active component inosine and the dipeptide methylester L-Phe-Phe-OMe on isolated protoscoleces of Echinococcus multilocularis for 24 and 48 h. Isoprinosine and inosine showed dose- and time-dependent activity, the latter displaying a more rapid effect than the former. A high activity was shown with L-Phe-Phe-OMe, when compared to praziquantel. Ultrastructural alterations were much more striking with L-Phe-Phe-OMe, with an effect similar to that of praziquantel, whereas the chemotherapeutic activity of inosine and isoprinosine appeared to be directed against a metabolic target, with a lethal effect not immediately visible at the ultrastructural level. Thus, the previously reported in vivo activities of these drugs result largely from a direct effect on the parasite.
No To Hattatsu. 2004 Jan;36(1):70-4.
Oshiro S, Minema H, Shiroma N, Hirayasu K, Nakada Y.
Department of Pediatrics, Okinawa Seishi Ryogoen, Naha, Okinawa.
Five patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon and inosinpranobex.
We followed up 5 patients with subacute sclerosing panencephalitis (SSPE) for 14 to 81 months. They were treated with alpha-interferon (INF-alpha) and oral inosinpranobex (INP) in an early stage of Jabbour stage II and within 5 months after the onset. On admission, Ommaya reservoir was implanted for the intrathecal administration of INF-alpha. The dose was 1 x 10(5) U/m2 initially and daily increased to 1 x 10(6) U/m2. A total dose of 30 x 10(6) U/m3 was given to them over a 4-weeks to 6-weeks period. After discharge, a dose of 15 x 10(6) U/m2 in three patients was given weekly and a dose of 30 x 10(6) U/m2 in the other patients. In addition, all patients received oral INP. One patient showed mild progression and remained in early stage of Jabbour stage II. In the remaining 4 patients, the disease progressed to Jabbour stage III. Despite the small number of patients studied here, the results suggest that treatment with INF-alpha plus oral INP is ineffective in an early stage of SSPE.
Isoprinosine description...
|
|
Drug category:Immunostimulators
 Isoprinosine scientific update
|
|
My Basket